PubMed Health⌕ Search

Biomedical subjects

A Ruibal Morell

Publications and source records attributed to A Ruibal Morell.

At least 19 recordsLinked to original sources
PubMed2002

[The Spanish Journal of Nuclear Medicine: from 1991 to 2000].

OBJECTIVE: To describe the articles published in "Revista Española de Medicina Nuclear" (REMN) from 1991 through 2000. MATERIAL AND METHODS: Five hundred and forty-two articles (originals, reviews, editorials, letters, clinical notes and images of interest) published in REMN during the past 10 years (1991-2000) were gathered. The following variables were assessed: topic, procedure, type of article, number of authors, Spanish region affiliation, country, number of pages and number of references. The results for the five year periods 1991-1995 and 1996-2000 were also presented. RESULTS: Excluding the editorial contributions, the most dealt with topic was the osteoarticular system (14.9%), followed by the heart (14.2%), endocrinology (12.1%), gastroenterology (11.3%) and neurology (10,3%). One hundred and thirty articles were linked to oncology. Madrid (23.7%), Catalonia (22.5%), Andalucia (10.6%) and Aragon (10.1%) were the Spanish regions that made the most contributions. Conventional planar scintigraphic studies were the most used procedure (49.1%), followed by SPECT (16.6%). The countries that were represented most were Spain and Cuba, with 410 and 36 works, respectively. The global trend underwent little change in the above variables in the decade. The pages/paper index was 6.1 +/- 1.7 for original papers and 6.5 +/- 4.3 for reviews. The authors/paper index was 6.3 +/- 2.3 for original papers and 2.7 +/- 2.1 for reviews. The references/paper index was 21.9 +/- 11.4 for original papers and 3+/- 1.1 39.6 for reviews. These three indexes increased in all sections between the periods 1991-1995 and 1996-2000. CONCLUSIONS: This survey shows subtle qualitative changes throughout the period analyzed. A quantitative increase in the scientific production in the REMN seems to exist. However, many factors must be considered in the final evaluation of these results and this remains beyond the scope of this descriptive work.

Bibliometrics↗
PubMed1999

Gastric carcinoma: expression of c-erbB-2/neu oncoprotein, epidermal growth factor receptor, cathepsin D, progesterone receptor and tumor associated glycoprotein-72 in different histological types.

OBJECTIVE: Gastric carcinoma can be divided into two main histological and clinical types: diffuse and intestinal. The aim of this study was to investigate the expression of neu/c-erbB-2 oncoprotein, epidermal growth factor receptor (EGFR), cathepsin D (catD), progesterone receptor (PR) and tumor-associated glycoprotein-72 (TAG-72) in gastric carcinoma of these histological types. METHOD: In this randomized, prospective study we analyzed 85 biopsy samples from patients with gastric adenocarcinoma. The control group consisted of 40 specimens from normal gastric mucosa. Neu oncoprotein and PR were determined by ELISA. CatD and TAG-72 were quantified with immunoradiometric (IRMA) methods, and EGFR were studied by radioimmunoassay (RIA). RESULTS: Neu, EGFR, catD and TAG-72 concentrations were higher in the tumoral group (p = 0.02, p = 0.00001, p = 0.002 and p = 0.007, respectively). In diffuse adenocarcinomas, catD and PR expression was increased (p = 0.01 and p = 0.04 respectively), whereas TAG-72 concentration, which correlated with neu (r = 0.57), was higher in the intestinal type (p = 0.04). No significant differences in EGFR and neu concentrations were seen between the two histological types. CONCLUSIONS: The higher PR and catD concentrations in diffuse adenocarcinomas, and the overexpression of TAG-72 in the intestinal type, support the existence of two modes of gastric carcinogenesis.

Adenocarcinoma↗
PubMed1988

Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study.

We assayed prostatic specific antigen and prostatic acid phosphatase serum levels in 1,383 patients using a double antibody radioimmunoassay (RIA) 125I. Establishing the upper normal limit in 10 ng/ml for prostatic specific antigen and 2.5 ng/ml for prostatic acid phosphatase, the false positive results were only 1.9 and 5.1% in men with nonprostatic benign or malignant pathology and 0 and 2.2% in women, respectively. We detected false positive levels in 3.5 and 4.7% of the patients with noncomplicated benign prostatic hypertrophy, 64.8 and 19.2% in complicated benign prostatic hypertrophy, 24 and 16% in acute prostatitis and 3.3% in chronic prostatitis for both tumoral markers. The sensibility in patients with prostate cancer was 87.2 and 64.1%, respectively, and there was better correlation with prostatic specific antigen than prostatic acid phosphatase levels on tumoral spread and histologic grading. Finally, the clinical efficacy was higher with prostatic specific antigen and it did not increase with the quantification of both tumoral markers.

Acid Phosphatase↗
PubMed1983

[Tumor markers].

Explore the source record for details and available documents.

Antigens, Neoplasm↗
PubMedDate not supplied

PET in abdominal pathology: advantages and limitations.

New oncologic procedures are currently more focused on the biological features of tumors. The ideal objective is the administration of personalized effective treatments for each patient that affects not just the location and spread of disease but also special metabolic characteristics of tumoral cells. Radiologic diagnostic methods are extremely important in the management of the patient for staging, restaging, and evaluation of treatment response, and clinicians are avid for some additional functional and metabolic information. Further, they need more dynamic methods for follow-up. Nuclear Medicine and positron emission tomography (PET) in many cases can meet this requirement, although it is not perfect, at least at the present time. Currently 2-((18)F)fluoro-2-desoxi-D: -glucose positron emission tomography is being widely used for oncologic purposes. Its information can be very useful in abdominal diseases and must be taken into account with the results of radiologic imaging. Thus, many changes in the choice of treatment are seen. However, it is very important to know that sometimes there is a lack of specificity that has to be considered.

Abdomen↗
PubMedDate not supplied

Clinical behaviour of prostatic specific antigen and prostatic acid phosphatase: a comparative study.

We assayed prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) serum levels in 1383 patients using a double antibody radioimmunoassay (RIA) I125. Establishing the upper normal limit in 10 ng/ml PSA and 2.5 ng/ml for PAP, the false positive results were only 1.9 and 5.1 percent in men with non-prostatic benign or malignant pathology and respectively 0 and 2.2 percent in women. We detected false positive levels for these two tumoral markers in 3.5 and 4.7 percent of patients with non-complicated benign prostatic hypertrophy, 64.8 and 19.2 percent in complicated benign prostatic hypertrophy, 24 and 16 percent in acute prostatitis and 3.3 percent in chronic prostatitis. The sensitivity in patients with prostate cancer was 87.2 percent for PSA and 64.1 percent for PAP, and there was a better correlation with PSA than PAP for tumoral spread and histological grading. Finally, clinical efficacy was higher with PSA and was no better when both markers were assayed.

Acid Phosphatase↗
PubMedDate not supplied

CEA serum levels in non-neoplastic disease.

Several non-neoplastic conditions, i.e., acute and chronic inflammations, benign tumors, renal or hepatic insufficiency, are associated with elevated plasma levels of Carcinoembryonic Antigen (CEA). Usually, CEA elevation in these pathologies is less than 10 ng/ml. CEA values in non-malignant disease can be affected by many factors, which can be classified into five main categories: a) tissular, b) physiological, c) metabolic, d) circulating and e) methodological factors. Synthesis, expression and release are the most important tissular factors. Among the metabolic ones liver, biliary and renal functions play a primary role in the determination of CEA concentrations. In addition, other factors such as the presence of circulating CEA-like substances, autoantibodies and immunocomplexes or the characteristics of the assay method can influence the diagnostic value of the CEA test. All these factors must be carefully considered when the marker is used in clinical practice.

Carcinoembryonic Antigen↗
PubMedDate not supplied

Clinical utility of hyaluronic acid values in serum and bronchoalveolar lavage fluid as tumor marker for bronchogenic carcinoma.

Various authors have proposed the use of hyaluronic acid (HA) as a tumor marker. In order to analyze its usefulness as a marker in bronchogenic carcinoma, the most common carcinoma in men, we determined the HA values in serum and bronchoalveolar lavage fluid (BAL). We performed prospective studies on two groups of patients: 81 diagnosed as having bronchial carcinoma and 34 with benign respiratory diseases. HA values were higher in patients with cancer than in those with benign diseases (serum: 79.8 ng/ml vs 63.7 ng/ml; BAL: 927 ng/mg vs 522 ng/mg). Also, the percentage of patients with levels exceeding the established cutoff was greater in the group with cancer than in the group with benign disease (serum: 24.6 vs 17.6; BAL: 25.3 vs 3). Statistically significant differences in these percentages were found in BAL (p<0.01). Patients with extended small cell carcinoma had higher HA values (p =0.04) than those with limited disease, and the percentage of patients with abnormal HA values was larger in the group with extended disease than in the group with limited disease (p = 0.004). The serial determinations of HA values in serum reflected the clinical evolution after treatment in 73% of the small cell carcinomas. Most of the patients with benign diseases whose HA values exceeded the cutoff level suffered from acute infectious dis-eases. Once these cases were excluded, the specificity of HA value determination in the diagnosis of carcinoma was very high (serum 96%, BAL 100%). The determination of HA levels in serum or BAL did not have any prognostic value in this study. We conclude that the HA levels in serum and BAL could be of interest as a tumor marker, especially in patients with small cell carcinoma.

Adenocarcinoma↗